Form 4: Organon & Co. Executive Vittorio Nisita Reports Acquisition of Stock Options and Restricted Stock Units

Vittorio Nisita, Head of Global Business Services at Organon & Co., reports the acquisition of stock options and restricted stock units.

Summary

• On March 29, 2024, Vittorio Nisita, Head of Global Business Services at Organon & Co., reported the acquisition of 70,806 stock options and 17,287 restricted stock units (RSUs).
• The stock options have an exercise price of $18.80 and vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
• The RSUs represent a contingent right to receive one share of Organon common stock for each RSU and vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
• Following the reported transaction, Nisita directly owns 70,806 stock options and 17,287 RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning executive interests with shareholder value. There are no red flags or negative implications.

Positives

• The grant of stock options and RSUs to a key executive like Vittorio Nisita aligns his interests with those of the shareholders.
• The vesting schedule of the options and RSUs encourages long-term commitment from the executive.

Industry Context

This type of equity grant is a common practice in publicly traded companies to incentivize and retain key executives.

Comparison to Industry Standards

• Equity compensation packages for executives in the pharmaceutical industry typically include a mix of stock options and restricted stock units.
• The vesting schedules are fairly standard, often spread over three to four years to encourage long-term performance.

Stakeholder Impact

• Shareholders: Aligns executive compensation with company performance.
• Employees: May boost morale by demonstrating investment in leadership.
• Executive: Incentivizes Vittorio Nisita to contribute to the long-term success of Organon & Co.

Key Dates